SCHEMBL20276070

SCHEMBL20276070

CC(C)C1CC(=O)N(c2ccc(-c3c4ccc(=O)cc-4oc4cc(O)ccc34)c(C(=O)O)c2)C1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 3/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ MEN1 O00255 2/20 0.49
▸ POLB P06746 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ ALPL P05186 1/20 0.49
▸ ALPI P09923 1/20 0.49
▸ ALPG P10696 1/20 0.49
▸ ATM Q13315 1/20 0.47
▸ PLEC Q15149 1/20 0.47
▸ CA9 Q16790 11/20 0.47
▸ CA1 P00915 9/20 0.47
▸ CA2 P00918 9/20 0.47
▸ DNASE1L3 Q13609 1/20 0.47
▸ PRMT1 Q99873 1/20 0.47
▸ CA12 O43570 3/20 0.45
▸ ELF3 P78545 4/20 0.45
▸ MED23 Q9ULK4 4/20 0.45
▸ ADRA1D P25100 1/20 0.44
▸ ADRA1A P35348 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12134945 0.89 USP2 (0.60) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL12706329 0.87 USP2 (0.58) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL14586590 0.85 USP2 (0.55) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL22651493 0.84 USP2 (0.68) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL1103795 0.81 USP2 (0.69) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL16283416 0.80 USP2 (0.67) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL12637647 0.77 USP2 (0.72) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL14415288 0.77 FOLH1 (0.49) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL16541409 0.77 USP2 (0.68) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL10098714 0.76 USP2 (0.76) USP2L3MBTL1MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11872291-B2 Fibroblast activation protein (FAP)-targeted imaging and therapy PURDUE RESEARCH FOUNDATION (US) 2024-01-16 — — US disclosed
EP-3555627-B1 FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY PURDUE RESEARCH FOUNDATION (US) 2023-11-22 — — EP disclosed
WO-2018111989-A1 FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY PURDUE RESEARCH FOUNDATION (US) 2018-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11872291-B2 Fibroblast activation protein (FAP)-targeted imaging and therapy FAP, FIBP, FRS2 USP2 1180/4885L3MBTL1 3795/4885MEN1 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback